Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) - Fukuoka, M; Wu, Y L; Thongprasert, S (J Clin Oncol, 2011)
et al.